COSMO PHARMACEUTICALS N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.05 CHF | -1.66% |
|
+4.35% | +45.97% |
| Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
| Mar. 20 | Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025 | CI |
Evolution of the average Target Price on Cosmo Pharmaceuticals N.V.
Price target over the last 5 years
History of analyst recommendation changes
b37b8fe10f3eb0345a8fe6fa78.eUaZOcZ8Gu_0uosU2J71_UwHNJ41KtA92cmbuZRPo_8.JhXyXb8TadrD8shdsMGd0AY3f9lPX4IMjLnj1KAL8aU6Fdd3_h17vbmN-A~8f627168dfa96201d6de25d56ea8155e
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
77.1
EUR
Average target price
95.63
EUR
Spread / Average Target
+24.04%
High Price Target
112.7
EUR
Spread / Highest target
+46.18%
Low Price Target
81.69
EUR
Spread / Lowest Target
+5.95%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Cosmo Pharmaceuticals N.V.
| Berenberg Bank | |
| Research Capital |
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
- Stock Market
- Equities
- COPN Stock
- Consensus Cosmo Pharmaceuticals N.V.
